This study is testing a new medicine called OTS167 for women with advanced breast cancer, including a tough type known as triple negative breast cancer (TNBC). The goal is to find the safest dose that can be given in a capsule form to patients. To join, women need to be 18 or older and have cancer that is not responding to standard treatments. They must be able to undergo tests and give consent to participate. Some people cannot join, like those with severe heart issues, certain infections, or if they're pregnant. The study involves taking the medicine, attending regular check-ups, and maybe having a biopsy, which is a small sample of body tissue taken for testing.
- Duration: The study requires multiple visits to the doctor for check-ups.
- Eligibility: Only women with certain types of advanced breast cancer can participate.
- Risks and Safety: Participants must have no severe health issues, like heart disease, to ensure safety.
How understandable was the trial content above?
Hard to understand
Easy to understand